Company intelligence / Profile preview
Hefei TG ImmunoPharma Co., Ltd.
Hefei, Anhui Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has received FDA clearance for clinical trials of TGI-2 (anti-PVRIG therapeutic antibody) and TGI-6 (bispecific antibody). TGI-2 has initiated Phase 1 trials in the United States. TGI-6 has demonstrated superior anti-tumor activity and safety in preclinical studies and is in Phase 1 trials for locally advanced/metastatic solid tumors.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodiesBispecific antibodiesTrispecific antibodiesNK/T-cell engagersImmunocytokinesBiological products
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Seeking global partners for development, clinical trials, and commercialization
Beyond the preview
Go deeper on Hefei TG ImmunoPharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hefei TG ImmunoPharma Co., Ltd..